Horizon Therapeutics Public Limited Company (HZNP) Stock Chart - Revenue & Earnings | Quarter Chart

Select dashboard ▾ New custom dashboard
Income Statement▲

Revenue by Product

Orphan Segment Net SalesT E P E Z Z AK R Y S T E X X AR A V I C T IP R O C Y S B IActimmuneInflammationR A Y O SP E N N S A I D Two PercentU P L I Z N AB U P H E N Y LQ U I N S A I RD U E X I S ProductVimovo
0250M500M750M1B1B2B2B2BQ2 2022Q3 2022Q4 2022Q1 2023Q2 20230250M500M750M1B1B2B2B2BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Revenue by Geography

UNITED STATESNon UsNon-US
0125M250M375M500M625M750M875M1BQ2 2022Q3 2022Q4 2022Q1 2023Q2 20230125M250M375M500M625M750M875M1BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0375M750M1B2B2B2B3B3BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
075M150M225M300M375M450M525M600MQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

EBITDA

EBITDA
050M100M150M200M250M300M350M400MQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

EPS

EPSEPS Diluted
000111222Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Revenue Variation (%)

Revenue Variation
-20-15-10-505101520Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
062125188250312375438500Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Revenue YoY Variation (%)

Revenue YoY Variation
-20-16-13-9-6-2259Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Price-to-Earning Ratio

P/E Ratio
0255075100125150175200Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0918263544526170Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Per Share Metrics

Operating IncomeTotal Other Income Expenses NetNet Income
050M100M150M200M250M300M350M400MQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
012344567Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023
Cash Flow Statement▲

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0112M225M338M450M562M675M788M900MQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Cash Flow to Debt Ratio

Cash At End Of Period
0375M750M1B2B2B2B3B3BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023
Balance Sheet▲

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
062M125M188M250M312M375M438M500MQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Quick Ratio

Total AssetsTotal Liabilities
02B5B8B10B12B15B18B20BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Cash & Equivalents

Total Current AssetsTotal Non Current Assets
01B2B4B5B6B8B9B10BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities
0625M1B2B2B3B4B4B5BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Total Liabilities

Total Stockholders Equity
0750M2B2B3B4B4B5B6BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Shareholders Equity

Debt To Equity
000001111Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Asset Composition

Cash And Cash EquivalentsShort Term Investments
0375M750M1B2B2B2B3B3BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023

Debt Structure

Short Term DebtLong Term Debt
0375M750M1B2B2B2B3B3BQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023
Key Metrics▼

Horizon Therapeutics Public Limited Company (HZNP) quarterly earnings & revenue

Horizon Therapeutics Public Limited Company (HZNP) reported revenue of $944.96M for Q2 2023, up 7.8% year-over-year, with net income of $127.07M and diluted EPS of $0.54.

Over the last four reported quarters, Horizon Therapeutics Public Limited Company generated $3.64B in revenue and $438.00M in net income.

Horizon Therapeutics Public Limited Company's next earnings report is scheduled for August 8, 2023.

Horizon Therapeutics Public Limited Company quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q2 2023$944.96M+7.8%$127.07M$0.54
Q1 2023$832.06M-6.0%$54.68M$0.23
Q4 2022$942.03M-7.1%$120.41M$0.52
Q3 2022$925.36M-10.8%$135.84M$0.58
Q2 2022$876.41M+5.3%$60.97M$0.26
Q1 2022$885.25M+158.5%$204.26M$0.87
Q4 2021$1.01B+36.1%$173.18M$0.73
Q3 2021$1.04B+62.9%$326.54M$1.38

📈 See Horizon Therapeutics Public Limited Company revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Horizon Therapeutics Public Limited Company (HZNP) — frequently asked questions

When does Horizon Therapeutics Public Limited Company (HZNP) report earnings next?

Horizon Therapeutics Public Limited Company is expected to report earnings on August 8, 2023.

What was HZNP's revenue last quarter?

Horizon Therapeutics Public Limited Company reported revenue of $944.96M in Q2 2023, up 7.8% from the same quarter a year earlier.

What was HZNP's EPS last quarter?

Horizon Therapeutics Public Limited Company reported diluted EPS of $0.54 in Q2 2023.

Is Horizon Therapeutics Public Limited Company profitable?

Horizon Therapeutics Public Limited Company is currently profitable, with $438.00M in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)

Horizon Therapeutics Public Limited Company valuation & key metrics →